Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways

PLoS Pathogens

Volumn 5, Issue 9, 2009, Pages

  Rong, Rong ^a,b   Li, Bing ^b   Lynch, Rebecca M ^a,b   Haaland, Richard E ^a,b,j   Murphy, Megan K ^a,b   Mulenga, Joseph ^c,d   Allen, Susan A ^c,e   Pinter, Abraham ^f,g   Shaw, George M ^h   Hunter, Eric ^a,b   Robinson, James E ⁱ   Gnanakaran, S ^a   Derdeyn, Cynthia A ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ZEHRP   (Zambia)

^d Zambia Blood Transfusion Service   (Zambia)

^e EMORY UNIVERSITY   (United States)

^f PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYBRIDOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OSCILLATION; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; VIRUS ENVELOPE; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS SURVIVAL; ACUTE DISEASE; ANTIBODY SPECIFICITY; CELL LINE; DRUG EFFECT; GENETICS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MUTATION; PHYSIOLOGY; SERODIAGNOSIS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIBODY DIVERSITY; CELL LINE; DNA MUTATIONAL ANALYSIS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTATION; NEUTRALIZATION TESTS; VIRUS REPLICATION;

EID: 70349695689     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000594     Document Type: Article

References (54)

1. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 358: 1590-1602.
2. Hemelaar J, Gouws E,Ghys PD, Osmanov S (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-23. (Pubitemid 44611051)
3. Hunter E (1997) Viral Entry and Receptors. In: John M. Coffin SHH, and Harold E. Varmus, eds.Retroviruses. Plainview: Cold Spring Harbor Laboratory Press. pp 71-121.
4. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113.
5. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. (Pubitemid 28289647)
6. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, et al. (2005) Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433: 834-841. (Pubitemid 40314887)
7. Barin F, McLane MF, Allan JS, Lee TH, Groopman JE, et al. (1985) Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science 228: 1094-1096. (Pubitemid 15227369)
8. Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, et al. (1985) Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228: 1091-1094. (Pubitemid 15227368)
9. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature.
10. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, et al. (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78: 5205-5215. (Pubitemid 38581472)
11. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682. (Pubitemid 36764500)
12. Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, et al. (2009) Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 83: 1240-1259.
13. Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, et al. (2004) Development of the antibody response in acute HIV-1 infection. AIDS 18: 371-381. (Pubitemid 38365863)
14. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H (2008) Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection. J Virol 82: 7932-7941.
15. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, et al. (2006) Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80: 5211-5218. (Pubitemid 43752766)
16. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, et al. (2007) Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81: 6187-6196. (Pubitemid 46878025)
17. Wei X, Decker JM,Wang S, Hui H, Kappes JC,Wu X, Salazar JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM (2003) Antibody Neutralization and Escape by HIV-1. Nature 422: 307-312.
18. Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen L, et al. (1992) Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr 5: 303-307.
19. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149. (Pubitemid 36418171)
20. Lynch RM, Shen T, Gnanakaran S, Derdeyn CA (2009) Appreciating HIV type 1 diversity: subtype differences in Env. AIDS Res Hum Retroviruses 25: 237-248.
21. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-11790. (Pubitemid 44788890)
22. Patel MB, Hoffman NG, Swanstrom R (2007) Subtype-Specific Conformational Differences Within the V3 Region of Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Protein. J Virol 82: 903-916.
23. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, et al. (2007) The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Hiv-1 Subtype C Infection. J Virol 82: 1860-1869.
24. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, et al. (2007) Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81: 1350-1359. (Pubitemid 46167856)
25. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, et al. (2007) Unique Mutational Patterns in the Envelope a2 Amphipathic Helix and Acquisition of Length in gp120 Hyper-variable Domains are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus type 1. J Virol 81: 5658-5668. (Pubitemid 46847005)
26. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, et al. (1990) Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. Aids 4: 107-112. (Pubitemid 20108767)
27. Geffin R, Hutto C, Andrew C, Scott GB (2003) A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology 310: 207-215. (Pubitemid 37487622)
28. Stipp HL, Kumar A, Narayan O (2000) Characterization of immune escape viruses from a macaque immunized with live-virus vaccine and challenged with pathogenic SHIVKU-1. AIDS Res Hum Retroviruses 16: 1573-1580. (Pubitemid 30765752)
29. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ (1999) Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 73: 5294-5300. (Pubitemid 29274810)
30. Blay WM, Gnanakaran S, Foley B, Doria-Rose NA, Korber BT, et al. (2006) Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques. J Virol 80: 999-1014. (Pubitemid 43062911)
31. Etemad-Moghadam B, Sun Y, Nicholson EK, Karlsson GB, Schenten D, et al. (1999) Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J Virol 73: 8873-8879. (Pubitemid 29441757)
32. Laird ME, Igarashi T, Martin MA, Desrosiers RC (2008) Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol 82: 11054-11065.
33. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005) Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 102: 18514-18519. (Pubitemid 43011257)
34. Kinsey NE, Anderson MG, Unangst TJ, Joag SV, Narayan O, et al. (1996) Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Virology 221: 14-21. (Pubitemid 26266538)
35. Rudensey LM, Kimata JT, Long EM, Chackerian B, Overbaugh J (1998) Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition. J Virol 72: 209-217. (Pubitemid 28048830)
36. Chackerian B, Rudensey LM, Overbaugh J (1997) Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 71: 7719-7727. (Pubitemid 27391717)
37. Reitter JN, Means RE, Desrosiers RC (1998) A role for carbohydrates in immune evasion in AIDS. Nat Med 4: 679-684.
38. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, et al. (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5: e1000274. doi:10.1371/journal.ppat.1000274.
39. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737. (Pubitemid 46279718)
40. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463.
41. Kulkarni SS, Lapedes A, Tang H, Gnanakaran S, Daniels MG, et al. (2009) Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 385: 505-520.
42. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, et al. (2007) Clade Specific Differences in HIV-1: Diversity and Correlations in C3-V4 Regions of gp120. J Virol 81: 4886-4891.
43. McKenna SL, Muyinda GK, Roth D, Mwali M, Ng'andu N, et al. (1997) Rapid HIV testing and counseling for voluntary testing centers in Africa. Aids 11 Suppl 1: S103-110.
44. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82: 3952-3970.
45. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission. Science 303: 2019-2022. (Pubitemid 38393277)
46. Robinson JE, Holton D, Pacheco-Morell S, Liu J, McMurdo H (1990) Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res Hum Retroviruses 6: 567-579. (Pubitemid 20380022)
47. Xiang SH, Wang L, Abreu M, Huang CC, Kwong PD, et al. (2003) Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 315: 124-134. (Pubitemid 37345175)
48. Robinson JE, Elliott DH, Martin EA, Micken K, Rosenberg ES (2005) High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection. Hum Antibodies 14: 115-121. (Pubitemid 43748241)
49. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10: 871-875. (Pubitemid 39070862)
50. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: e178. doi:10.1371/journal.pmed.0040178. (Pubitemid 46842583)
51. Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D, et al. (2006) Understanding and making use of human memory B cells. Immunol Rev 211: 303-309. (Pubitemid 43882981)
52. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE (2002) Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses 18: 1207-1217. (Pubitemid 35370609)
53. Decker JM, Bibollet-Ruche F, Wei XP, Wang S, Levy DN, et al. (2005) Antigenic Conservation and Immunogenicity of the HIV Coreceptor Binding Site. Journal of Experimental Medicine 201: 1-14. (Pubitemid 40664085)
54. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, et al. (2000) Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des 8: 1329-1339. (Pubitemid 32149759)